SCGB3A2 has been identified as a marker for pulmonary carcinoma in mice and humans [52], and MARCO has recently been identified as a possible candidate for targeted antibody therapy in non-small cell lung cancer [53]. The gene discussed is SCGB3A2; the disease is non-small cell lung carcinoma.